Combined use of induced pluripotent stem cell derived cardiomyocytes and 3D-heart tissue to develop Therapies for pediatric heart failure in Tetratology of Fallot.

• Conditions: pulmonary atresia with ventricular septal defect; Tetralogy of Fallot; 10010394

• Registration Number: NL-OMON51398
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 5

Inclusion Criteria

- Diagnosis as stated above
- Age between 0-18 years
- Known genetic mutation
- Written informed consent.

Exclusion Criteria

- Non-consent to collect blood or residual tissue obtained at surgery or
transplantation.
- Presence of multiple mutations or deletion of chromosome.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified